Kornimate/medical-research-clean huggingface dataset:
mindfulness as an add-on intervention in treatment for problem gambling in clinical settings in sweden

Conditions: Problem Gambling

Summary: this study will test the effects of an add-on mindfulness intervention for patients with gambling problems, added to treatment as usual, compared to a waitlist control condition. the study will primarily aim to decrease gambling behaviour compared to the control condition which receives the intervention later, after two months, and secondarily to decrease symptoms of depressive and anxiety symptoms. in addition, patients who have undergone the mindfulness intervention will be offered participation in a qualitative interview study aiming to deepen the understanding of feasibility and challenges of a mindfulness add-on intervention against gambling problems.


Eligibility criteria:
inclusion criteria: * enrolled in any kind of treatment for problem gambling at a regional health care unit for problem gambling or at any municipal social service unit for problem gambling, and who provides informed consent exclusion criteria: * inability to provide informed consent due to language difficulties or due to severe mental health problems, or because of mental health problems requiring urgent psychiatric management (such as suicidal, homicidal, delirious or psychotic behavior)

Keywords: problem gambling mindfulness
study of preoperative docetaxel or cisplatin (cddp) + docetaxel for c-stage ib-ii non-small cell lung cancer (nsclc)

Conditions: Pulmonary Neoplasms

Summary: the purpose of this study is to evaluate the safety and efficacy of the preoperative docetaxel and docetaxel-cisplatin combination in c-stage ib/ii nsclc, and select the optimal preoperative therapy for phase iii trials.

preoperative chemotherapy has substantial theoretical advantage. several controlled trials are under way in early stage (clinical stage ib-ii) nonsmall cell lung cancer (nsclc). in each trial, platinum-based doublet chemotherapy is employed. although platinum-based doublet is the treatment of choice for advanced nsclc, risk/benefit balance might well be different in earlier stages. there have been no prospective randomized trials to choose an optimal preoperative chemotherapy in early stage nsclc. comparison: preoperative cisplatin-docetaxel combination versus docetaxel monotherapy in clinical stage ib/ii nsclc.

Eligibility criteria:
inclusion criteria: * newly diagnosed, pathologically documented nsclc * clinical stages ib (t2n0m0), iia (t1n1m0) or iib (t2n1m0 or t3n0m0) * ages: 15-74 years old * ecog performance status 0 or 1 * measurable disease * ample organ function * signed informed consent exclusion criteria: * invasion to the first rib or more superior chest wall * metastasis to, or involvement of, mediastinal node * active concomitant malignancy * unstable angina, recent myocardial infarction, or heart failure * uncontrolled diabetes or hypertension * pregnant or lactating women * other severe complications * systemic use of corticosteroids

Keywords: pulmonary neoplasm preoperative chemotherapy cisplatin, docetaxel randomized trial clinical stage ib or ii nonsmall cell lung cancer
assess the safety and pharmacokinetics of ascending, multiple oral doses of spd489 in adults with schizophrenia

Conditions: Schizophrenia

Summary: this is a multiple ascending dose study; the purpose of this study is to examine the safety, tolerability and pharmacokinetics (levels of drug in the blood) of spd489 in schizophrenic patients who are currently maintained on a stable dose of an antipsychotic medication.


Eligibility criteria:
subjects must be diagnosed with schizophrenia, on a stable dose of an antipsychotic and not have any cardiac risk factors

Keywords: schizophrenia
pain relief by platelet-rich plasma (prp) treatment

Conditions: Sciatica

Summary: past prp therapy is not sufficient for some part of patients.in this clinical research, the integrated application of prp with extracellurar matrix and some type of stem cell technique.


Eligibility criteria:
inclusion criteria: * injury by professional sports and non professional sports exclusion criteria: * other basic disease holder
diabetes intervention accentuating diet and enhancing metabolism

Conditions: Diabetes Mellitus, Type 2

Summary: diabetes is one of the greatest challenges faced by healthcare services worldwide. it is associated with serious complications such as heart attacks, stroke, and peripheral artery disease as well as kidney disease, eye disease, and nerve dysfunction. data from weight loss with bariatric surgery suggest that with the appropriate intervention, it should be possible to reverse diabetes and that the earlier the intervention occurs, the greater the chances of placing diabetes into remission. there is now a need to translate this knowledge into the medical care of younger patients with early diabetes who are overweight/obese. the aim of this study is to see if younger adult patients with overweight/obesity and type 2 diabetes who are participants in a programme incorporating a low energy diet and physical activity (lifestyle) will lower their weight, cardiovascular risk and improve their glycaemic control as compared to the usual care.

the aim of the proposed study is to conduct a pragmatic randomised controlled clinical trial randomising young adult patients with obesity and type 2 diabetes to an intervention incorporating a low calorie diet and physical activity or usual care. the investigators hypothesise that patients in the low calorie intervention arm will have greater weight reduction leading to significant improvement in glycaemic control and cardiovascular risk. the primary outcome will be weight loss. the low calorie diet intervention arm is designed to achieve and maintain significant weight loss through decreased calorie intake, increased physical activity, and behaviour change. usual care will include routine advice about diet and physical activity. secondary outcomes include diabetes control, body composition, and quality of life.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (based on ada diagnostic criteria) ; * diabetes of ≤ 3-year duration; * bmi \>27.0 kg/m² (based on who cut-points for ethnicity 119); * men and women; * age 18-50 years; * originating from the middle east and north africa region and resident in qatar; * able to commit to the study duration; * able to give informed consent and willing to participate in the study. exclusion criteria: * type 1 diabetes mellitus based on clinical history; * cardiovascular event in the previous 6 months; * chronic kidney disease stage 3b or greater (egfr \<30 ml/min/1.73m²); * currently pregnant, lactating, or planning pregnancy within the study period; * any condition precipitating fluid overload such as heart failure (nyha class \> i) and liver cirrhosis; * significant previously diagnosed psychiatric disorder (e.g. schizophrenia, post-traumatic stress disorder, obsessive-compulsive disorder); * uncontrolled depression (based on hospital anxiety and depression scale); * uncontrolled epilepsy; * known lactose intolerance; * severe arthritis preventing walking; * active gout; * active gallstone disease or known asymptomatic gallstones.
pharmacokinetics of ketamine in infants and children

Conditions: The Pk of IV Ketamine in Children With Heart Disease

Summary: dosing of medications is based on the plasma level achieved with a given dose and how long the medicine remains in the body. this study is called pharmacokinetics-that is, what the body does to the medication. ketamine is an intravenous medication used for anesthesia and sedation in children. however the pharmacokinetics of ketamine has not been systematically studied. we propose to study the pharmacokinetics of ketamine in different age groups of children ranging from infants to teenagers.

this is an open label study that will be conducted in infants and children presenting for procedures (eg., surgery or cardiac catheterization) at stanford and lucile packard children's hospital in california and at the children's hospital in denver, co. patients with abnormal kidney or liver functions will be excluded from the study as the dysfunction in these organs affects the clearance of medications from the body and affects dosing. preterm neonates will also be excluded. all patients will be premedicated and anesthetised at the discretion of the anesthesia faculty providing clinical care for the child. once the patient's procedure is underway, a 0.5 cc blood sample will be drawn from an intravenous line. this is the preload blood sample (t0). following this a 2mg/kg intravenous bolus of ketamine will be administered over 5 minutes (this is the usual dose and manner in which ketamine is administered). five minutes after the bolus, timed blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus. (total 14 blood samples; total blood required is 7 mls for the entire study). when the procedure is completed the anesthesiologist will awaken the patient as per their usual practice. blood samples that still need drawing will be done in the post-anesthesia recovery room or intensive care or ward-any location where the patient is likely to remain after the surgery.

Eligibility criteria:
inclusion criteria: * term infants (38 weeks gestation)and infants and children up to age 18 years. * patients who require procedures that necessitate at least 8 hours in the hospital and those being admitted after procedure will be eligible to participate. * patients who will receive ketamine as part of their standard anesthesia regimen. exclusion criteria: * preterm neonates * liver disease * kidney disease * heart failure * sepsis * patients receiving anticonvulsants or barbiturates

Keywords: anesthesia children ketamine pharmacokinetics
observational retrospective study on clinical outcomes of patients receiving benralizumab in spain.

Conditions: Severe Asthma

Summary: primary objectives: 1. to describe the demographic and baseline characteristics in patients with severe eosinophilic asthma in spain who received at least one dose of benralizumab, after its marketing authorization 2. to describe background treatment patterns of severe eosinophilic asthma patients at baseline and after the index date (benralizumab initiation) this is a descriptive, observational, multi-centre, longitudinal, retrospective cohort study in adults patients (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who, at the discretion of the physician, received benralizumab accordingly to the clinical practice, in the period after the marketing authorization of benralizumab in spain, on january 1st 2019.


Eligibility criteria:
inclusion criteria: * adult patients (age ≥18 years) * diagnosis of severe eosinophilic asthma requiring stable treatment of high doses of inhaled corticosteroids and a long-acting agonist β2 ± additional asthma controller. * patients with at least 12-month data available before index date (starting benralizumab treatment) * patients with at least 3-month electronic medical records data available from first benralizumab dose ("index date") * informed consent signed. exclusion criteria: * patients who received benralizumab in a clinicaltrial, during the observation period.
exercise impact in elderly with multimorbidity: hba1c and blood pressure

Conditions: Hypertension; Diabetes; Osteoarthritis; Depression Disorders; Multimorbidity; Respiratory Disorders; Sarcopenia in Elderly; Dyslipidemia; High Blood Cholesterol; Obese Patients

Summary: the main objective of the study is to compare the effect of two different types of physical exercise modalities on glycated hemoglobin and blood pressure in elderly individuals with multimorbidity. the main characteristic of the proposal is that it is experimental, with two intervention groups with physical exercise that will be randomized in the order of participation of the groups and forwarded to the researchers regarding the evaluations and training periods. in addition, the study will be controlled, as it has a control group that will not perform any intervention with physical exercises during the study period. to allocate the participants in each exercise group and for the control group, the researchers will use the 1:1 method, the user will receive an automatic generator through the random.org website. the main questions raised by the studies will be: is land-based training more effective than aquatic training for this population in improving the primary outcomes? is there a difference between training at these intensities and not doing any physical exercise in this population with these primary outcomes? participants in the 2 intervention groups will: train 3x per week for 10 weeks at intensities that will progress over the weeks.


Eligibility criteria:
inclusion criteria: * being elderly adult 60 years old * having grade 1 medicated hypertension (systolic blood pressure ≥ 140 and diastolic blood pressure ≥ 90) or having type 2 diabetes mellitus * volunteers may have other morbidities such as: anxiety/depression, knee osteoarthritis or obesity * be fit for the practice of physical activity exclusion criteria: * being a smoker * have severe musculoskeletal problems that prevent you from carrying out physical activities * unable to carry out the protocol completely

Keywords: multimorbidity diabetes high blood pressure older people combined exercise aquatic exercise
gene expression changes of brain tissue in human temporal lobe epilepsy with hippocampal sclerosis

Conditions: Epilepsy; Hippocampal Sclerosis

Summary: epilepsy is a common neurological disease, manifested in the sudden abnormal discharge of neurons leading to short-term brain dysfunction, has become the neurology after headache the second most common disease. in china, the prevalence of epilepsy is about 4.7-8.5 per 1,000, and more than 400,000 new cases of epilepsy are developed each year. of these, 30% of patients were treated with ineffective medication, developing into a drug-incurable epilepsy that required surgery and other treatments. the most common type of epilepsy is temporal lobe epilepsy, while the common complication in temporal lobe epilepsy is hippocampal sclerosis, which often requires surgical removal. the incidence of inner temporal lobe epilepsy associated with hippocampal sclerosis is increasing, but its exact cause and specific pathogenesis are still unclear, so clarifying its pathogenesis will contribute to the understanding of temporal lobe epilepsy and the improvement of surgical procedures. this study is intended to get single-cell transcriptome as well as spatial transcriptome data of temporal lobe and hippocampus samples. by studying gene expression change associated with epilepsy and hippocampus sclerosis, we intended to find possible prognostic-related molecules and to deepen understanding of pathological changes in epilepsy at the molecular level.


Eligibility criteria:
inclusion criteria: * patients confirmed in our hospital as having temporal lobe epilepsy and intending surgery to remove temporal lobe and hippocampal tissue; * volunteer to participate in this clinical trial, comply with the requirements of this clinical trial and sign an informed consent form. exclusion criteria: * chronic diseases of the central nervous system other than temporal lobe epilepsy; * other patients that are not suitable for this clinical trial determined by the researchers;

Keywords: epilepsy hippocampal sclerosis
nutritional prevention of diabetes mellitus type 2

Conditions: Type 2 Diabetes Mellitus; Nutritional and Metabolic Diseases; Liver Fat; Insulin Sensitivity

Summary: this study investigates the influence of red meat and fibers on glucose metabolism and body fat composition in subjects at increased risk for type 2 diabetes.

the epidemiologic evidence for increased red meat intake and decreased fiber intake as risk factors for t2d is solid. however, few intervention studies have been performed in order to investigate the role of whole-grain intake or the consumption of red meat in glycemic control and prevention of diabetes, yielding contradicting results. thus, in order to prove causality, further identify potential underlying mechanisms and be able to improve lifestyle modification programs, we performed a randomized, controlled intervention study over six months. the participants are individuals at increased risk for tyoe 2 diabetes. they were randomised to 3 interventions groups: 1) caloric restriction of 400 kcal/day (control group), 2) caloric restriction plus no red meat consumption 3) caloric restriction and increase in fiber intake. subjects where thoroughly phenotyped by anthropometric parameters, oral glucose tolerance tests, and mri measurements of body fat composition and iron content in the liver. in this study, we want to compare the effectiveness of reduced caloric intake only versus reduced caloric intake with an additional modification of diet composition in terms of red meat and fiber consumption.

Eligibility criteria:
inclusion criteria: individuals at a high risk for type 2 diabetes: * positive family history of type 2 diabetes, * presence of metabolic syndrome, * body mass index (bmi) \> 27 kg/m2, * diagnosis of impaired glucose tolerance (igt) * previous diagnosis of gestational diabetes diabetes exclusion criteria: main exclusion criteria * diagnosis of type 1 or 2 diabetes mellitus * bmi \>45 kg/m² * presence of serious illness such as cardiovascular, malignant or psychiatric disease.
comparison of modified with conventional adaptive servoventilation processes

Conditions: Periodic Breathing; Cheyne-Stokes Respiration

Summary: the objective of this study is to compare the modified adaptive servoventilation control algorithm of the with the standardised algorithms of routinely-used servoventilation processes (autoset cs2) in terms of the effect on obstructive and central events. the aim is to normalise breathing during sleep and hence eliminate the sleep-related breathing disorder, resulting in even more effective treatment of nocturnal breathing disorders in patients with cardiovascular diseases and sleep apnoea, to ensure optimum therapy success.

patients with cardiovascular disorders frequently suffer from sleep-related respiratory disorders (srrd), such as obstructive sleep apnea (osa) or a specific form of central sleep apnea, cheyne-stokes breathing (csb, periodic breathing). however there is also a significant incidence of complex nocturnal breathing disorders, with both obstructive and central components. sleep-related breathing disorders of this kind cause decreases in arterial oxygen saturation through brief hypopneas and apneas. disturbed breathing also causes the patient to wake frequently during the night (arousals), usually during the hyperventilatory phase of csb. repeated arousals cause fragmentation of sleep, and therefore a deep sleep deficit. this leads to increased sleepiness during the day and impaired cognitive performance. previous studies have shown that cheyne-stokes breathing can be treated effectively with adaptive servoventilation. an enhancement to the routinely used algorithm (autoset cs2) has been created which allows the algorithm to differentiate between obstructive events and cheyne-stokes breathing, and better respond to apneas and hypopneas to eliminate the sleep-related breathing disorder and normalise breathing during sleep.

Eligibility criteria:
inclusion criteria: * 18+ years of age * consent in writing * complex nocturnal breathing disorder with cheyne-stokes breathing and obstructive sleep apnoea * ahi \> 15/h exclusion criteria: * acute cardiac decompensation * acute myocardial infarct within the last 3 months * post-resuscitation condition within the last 3 months * post-stroke condition with difficulty in swallowing or persisting hemiparesis * abuse of medication, alcohol or drugs * pregnancy * known to be suffering from a tumour
exploring the effects of strength training on depressive symptoms and cardiovascular risk in black men

Conditions: Depressive Symptoms

Summary: this study will address a gap in the literature and advance the field of minority men's health. specifically, it will be the first randomized controlled trial of resistance exercise as a dual intervention for depression symptoms and cvd risk reduction with depressed black men.


Eligibility criteria:
inclusion criteria: * experiencing depression symptoms and generally healthy. exclusion criteria: * anyone assessed to be unsafe to be enrolled.
a phase 2 clinical study of khk4827

Conditions: Moderate to Severe Plaque Psoriasis

Summary: this study is designed to evaluate the efficacy and safety of khk4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study. pharmacokinetics of khk4827 will also be assessed.


Eligibility criteria:
inclusion criteria: * subject has had stable moderate to severe plaque psoriasis for at least 6 months. * subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator. * subject has involved bsa ≥ 10% and pasi ≥ 12 at screening and at baseline. exclusion criteria: * subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication-exacerbated psoriasis. * evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of investigational product on psoriasis. * subject has any active common terminology criteria for adverse events (ctcae) grade 2 or higher infection * subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol. * subject has used the following therapies within 14 days of the first dose: topical calcineurin inhibitors including tacrolimus , topical vitamin a, activated form d3 or activated form d3 analogue preparations, weak through strong topical steroids (excluding application on the scalp, axillae, and groin) * subject has used the following therapies within 28 days of the first dose: any other systemic psoriasis therapy (eg, vitamin a, calcineurin inhibitors, methotrexates, steroids), uva therapy (with or without psoralen), very strong or strongest topical steroid, tar therapy * subject has used the following therapies within 3 months of the first dose: adalimumab, etanercept, infliximab, or live vaccines * subject has used ustekinumab within 6 months of the first dose * subject has previously used an anti-interleukin-17 biologic therapy